HGF Partner Craig Thomson will be Co-presenting "Creating Impact: The challenges and opportunities of commercialisation in the field of bacteriophage research" alongside Professor Martha RJ Clokie.
IP in Retail 2017 - HGF's fifth annual conference will be held in September in Leeds and London. The conference addresses topical IP issues for retailers.
When we look at the emerging and likely future battles being fought to establish dominance in the emerging field of CRISPR technologies, it may be too easy to conclude that one has no frame of reference to help understand what the conclusion will likely be. However, as Harry S Truman said; “There is nothing new in the world except the history you do not know”. There have, of course, been many emerging technologies that have been subject to an IP land-grab. One such instance that we will look at in this article relates to CpG oligonucleotides.
The UK has deposited the document required to apply the Protocol to the Agreement on a Unified Patent Court on provisional application (PPA) with the depository for the UPC Agreement.
A 5 year battle between Eli Lilly (Lilly) and Actavis centred on Lilly’s patent for the use of pemetrexed disodium for cancer therapy, has culminated in a decision from the UK Supreme Court, allowing Lilly’s appeal and deciding that Actavis' Products directly infringe Eli Lilly's patent in the UK, France, Italy and Spain. The Court also dismissed Actavis' cross-appeal on the basis that if its products did not directly infringe, they would indirectly infringe to the extent held by the Court of Appeal. Full judgment here.